Cargando…
Complement activation is a crucial pathogenic factor in catastrophic antiphospholipid syndrome
Autores principales: | Barratt-Due, Andreas, Fløisand, Yngvar, Orrem, Hilde L., Kvam, Ann K., Holme, Pål A., Bergseth, Grethe, Tjønnfjord, Geir E., Mollnes, Tom E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4911539/ https://www.ncbi.nlm.nih.gov/pubmed/27105662 http://dx.doi.org/10.1093/rheumatology/kew040 |
Ejemplares similares
-
Effect on mother and child of eculizumab given before caesarean section in a patient with severe antiphospholipid syndrome: A case report
por: Gustavsen, Alice, et al.
Publicado: (2017) -
Acute heart failure following myocardial infarction: complement activation correlates with the severity of heart failure in patients developing cardiogenic shock
por: Orrem, Hilde L., et al.
Publicado: (2018) -
Combined inhibition of C5 and CD14 efficiently attenuated the inflammatory response in a porcine model of meningococcal sepsis
por: Hellerud, Bernt C., et al.
Publicado: (2017) -
Clinical and Complement Long-Term Follow-Up of a Pediatric Patient with C3 Mutation-Related Atypical Hemolytic Uremic Syndrome
por: Bjerre, Anna, et al.
Publicado: (2018) -
Factor eight inhibitor bypass activity (FEIBA) in the management of bleeds in hemophilia patients with high-titer inhibitors
por: Tjønnfjord, Geir E, et al.
Publicado: (2007)